NCT00293020View on ClinicalTrials.gov

Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
PainCancer
Interventions
DRUG

BEMA Fentanyl

buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily

Trial Locations (1)

78746

ResearchPoint, Austin

Sponsors
All Listed Sponsors
lead

BioDelivery Sciences International

INDUSTRY

NCT00293020 - Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy | Biotech Hunter | Biotech Hunter